Results 291 to 300 of about 4,194,617 (361)

Therapeutic strategies for MMAE‐resistant bladder cancer through DPP4 inhibition

Molecular Oncology, EarlyView.
We established monomethyl auristatin E (MMAE)‐resistant bladder cancer (BC) cell lines by exposure to progressively increasing concentrations of MMAE in vitro. RNA sequencing showed DPP4 expression was increased in MMAE‐resistant BC cells. Both si‐DPP4 and the DPP4 inhibitor sitagliptin suppressed the viability of MMAE‐resistant BC cells.
Gang Li, Shuichi Tatarano, Hirofumi Yoshino, Saeki Saito, Mitsuhiko Tominaga, Junya Arima, Ikumi Fukuda, Takashi Sakaguchi, Ryosuke Matsushita, Yasutoshi Yamada, Hideki Enokida   +10 more
wiley   +1 more source

Readiness for Provision of Online Pharmaceutical Services by Retail Pharmacies in Kampala Metropolitan Area, Uganda. [PDF]

Integr Pharm Res Pract
Wadada AE, Blessed PPE, Munanura EI, Kageni P, Ategyeka PM, Elilu NJ, Kalidi R.   +6 more
europepmc   +1 more source

Infrared laser sampling of low volumes combined with shotgun lipidomics reveals lipid markers in palatine tonsil carcinoma

Molecular Oncology, EarlyView.
Nanosecond infrared laser (NIRL) low‐volume sampling combined with shotgun lipidomics uncovers distinct lipidome alterations in oropharyngeal squamous cell carcinoma (OPSCC) of the palatine tonsil. Several lipid species consistently differentiate tumor from healthy tissue, highlighting their potential as diagnostic markers.
Leonard Kerkhoff, Manuela Moritz, Dennis Eggert, Anna Worthmann, Joerg Heeren, Henrike Zech, Till S. Clauditz, Waldemar Wilczak, Hartmut Schlüter, Christian S. Betz, Arne Böttcher, Jan Hahn   +11 more
wiley   +1 more source

When one size does not fit all - New Zealand perspectives on the International Health Regulations during the COVID-19 pandemic. [PDF]

Global Health
Yim LW, Bullen C, Bloomfield A, McCool J.   +3 more
europepmc   +1 more source

Recurrent cancer‐associated ERBB4 mutations are transforming and confer resistance to targeted therapies

Molecular Oncology, EarlyView.
We show that the majority of the 18 analyzed recurrent cancer‐associated ERBB4 mutations are transforming. The most potent mutations are activating, co‐operate with other ERBB receptors, and are sensitive to pan‐ERBB inhibitors. Activating ERBB4 mutations also promote therapy resistance in EGFR‐mutant lung cancer.
Veera K. Ojala, Sini Ahonen, Sara Peltola, Aura Tuohisto‐Kokko, Olaya Esparta, Peppi Suominen, Anne Jokilammi, Iman Farahani, Deepankar Chakroborty, Nikol Dibus, Steffen Boettcher, Tomi T. Airenne, Mark S. Johnson, Lisa D. Eli, Klaus Elenius, Kari J. Kurppa   +15 more
wiley   +1 more source

Editorial: The future of agricultural biosafety regulations. [PDF]

Front Bioeng Biotechnol
Garcia-Alonso M, Rubinstein C, Smyth SJ, Vicien C.   +3 more
europepmc   +1 more source

On the history of abortion from antiquity to the present day, with a focus on Central Europe and Germany. [PDF]

Arch Gynecol Obstet
Dienerowitz FM, David M.
europepmc   +1 more source

National IHR authorities in the 2024 amendments to WHO's International Health Regulations: transforming the opportunity into reality. [PDF]

BMJ Glob Health
Aperce C, Habibi R.
europepmc   +1 more source

The further education loans regulations 2012 [PDF]

, 2012

core